From the Journals

COVID-19 antibody response not reduced with diabetes

Publish date: October 20, 2020

 

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
MDedge Cardiology
British protocol allows insulin-treated pilots to fly safely
MDedge Cardiology
Dapagliflozin’s CKD performance sends heart failure messages
MDedge Cardiology
Time to screen for liver disease in type 2 diabetes?
MDedge Cardiology
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
MDedge Cardiology
Empagliflozin cut PA pressures in heart failure patients
MDedge Cardiology
T2D treatments create tension between glycemic and cardiovascular goals
MDedge Cardiology
Entresto halves renal events in preserved EF heart failure patients
MDedge Cardiology
Substance in tears could be used for diabetes monitoring
MDedge Cardiology
Recall widens for diabetes drug metformin
MDedge Cardiology